Investment
Features
FeesSafety
Academy
More
Pluang+

Embecta shares plunge 25% after Q2 earnings miss and guidance cut, triggering securities investigation.

Market News
14 May 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

Embecta Corp.'s stock dropped over 25% following its Q2 FY2026 earnings report, which missed analyst expectations and included a lowered full-year revenue and earnings forecast. This sharp decline followed prior management statements that results were meeting or exceeding expectations. The significant stock drop has led to an investigation by law firm Levi & Korsinsky into potential securities law violations, focusing on whether Embecta adequately disclosed risks to investors. Investors who suffered losses are encouraged to contact the firm for a possible securities claim.

More News

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...

Market News
Bullish
2 hours ago
Rotork agrees to £4.1bn takeover by Swiss firm ABB, offering 73% premium to shareholders.

Rotork agrees to £4.1bn takeover by Swiss firm ABB, offering 73% premium to shareholders.

Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...

Company Fundamentals
Bullish
4 hours ago
Alexandria Real Estate Equities faces sharp stock drop amid high vacancy in life science hubs.

Alexandria Real Estate Equities faces sharp stock drop amid high vacancy in life science hubs.

Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...

Company Fundamentals
Bearish
4 hours ago
ASML raises 2026 revenue and margin outlook, boosts price target to $2510 with 41% upside potential.

ASML raises 2026 revenue and margin outlook, boosts price target to $2510 with 41% upside potential.

ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...

Analyst Insights
Bullish
4 hours ago
Labcorp seen as a steady growth buy with cost cuts offsetting healthcare pricing pressures

Labcorp seen as a steady growth buy with cost cuts offsetting healthcare pricing pressures

Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App